| Autor: |
Thabit, Hood, Mubita, Womba, Rubio, Jose, Karuppan, Mini, Schofield, Jonathan, Willinska, Malgorzata E., Hovorka, Roman, Leelarathna, Lalantha |
| Předmět: |
|
| Zdroj: |
Diabetes, Obesity & Metabolism; Apr2023, Vol. 25 Issue 4, p1121-1124, 4p |
| Abstrakt: |
Keywords: clinical trial; continuous glucose monitoring; CSII; insulin analogues; insulin pump therapy; insulin therapy EN clinical trial continuous glucose monitoring CSII insulin analogues insulin pump therapy insulin therapy 1121 1124 4 03/08/23 20230401 NES 230401 INTRODUCTION Carbohydrate counting to quantify prandial insulin requirement remains a key aspect of type 1 diabetes self-management.[1] This, however, remains challenging, leading to dysglycaemia and increased burden for many people with type 1 diabetes.[2] Current hybrid closed-loop systems still require manual meal (prandial) bolusing due to the relatively slow action of standard rapid-acting insulin. In conclusion, glucose control using the CamAPS FX closed-loop system under conditions of underestimated and missed meal bolus with faster-acting insulin aspart is comparable with insulin aspart. DISCUSSION Use of faster-acting insulin aspart compared to insulin aspart during closed loop when meal boluses were underestimated and missed led to comparable glycaemic outcomes, with no significant differences in closed-loop algorithm-mediated insulin doses. Comparison of faster-acting aspart with insulin aspart under conditions mimicking underestimation or missed meal boluses in type 1 diabetes using closed-loop insulin delivery. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text